{"entity":{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","aka":[],"tldr":"Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.","summary":"Anna Nowak (University of Western Australia) led the DREAM phase 2 trial, the first to show durvalumab can be combined with first-line platinum-pemetrexed in mesothelioma, and is co-principal investigator of the international DREAM3R phase 3 trial with PrE0506. Her laboratory work on chemotherapy-induced immune modulation underpins the chemo-immunotherapy approach in the disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab"}],"tags":["mesothelioma","immunotherapy","australia"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":["durvalumab"],"companies":[],"institutions":["university-of-western-australia"],"pathways":[],"terms":[],"trials":["dream3r"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-lung-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology and Dean of Medicine, University of Western Australia","institutionId":"university-of-western-australia","specialisms":["Mesothelioma","Immunotherapy","Chemo-immunotherapy combinations","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab"}],"papers":[{"title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30462-9"},{"title":"Chemotherapy with or without durvalumab in mesothelioma (DREAM3R): rationale and design","journal":"Clinical Lung Cancer","year":2021}],"orcid":"0000-0002-9317-9526"},"route":"/people/anna-nowak/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"institution":[{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/"}],"trial":[{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/"}],"journal":[{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/"}]}}